Seattle, United States
Rosetta Biosoftware has announced the availability of their new product, the Rosetta Syllego(TM) Genetic Data Management and Analysis System for genetic studies. The system is designed to effectively manage genetic data from disparate sources and combine relevant genotypic and phenotypic study data so that scientists can spend their time analyzing data and drawing conclusions instead of contending with data from multiple sources.
"Customers and prospects have shared with us their frustrations for finding a resource that can capture and store data from a range of sources, so we designed the Syllego system to address this need. The system enables researchers to plan and conduct genetic studies using various commercial genotyping platforms and vendor assays and integrate relevant study data," said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware. "Further, the system includes quality control tools to prevent loss of time in downstream analyses as well as automation and project management tools to record and plan analysis workflows and catalog data for future studies. All of these tools help scientists spend less time transforming and formatting data and more time analyzing data."
The Syllego system also includes basic data analysis tools and the ability to integrate study data with common statistical packages, such as R. The system will be demonstrated at the Human Genome Organisation conference in Helsinki, Finland, May 31 - June 3, as well at Rosetta Biosoftware's upcoming conference, the Rosetta Technology Forum, also in Helsinki, June 4 - 5. To register for this forum free of charge, please visit www.rosettabio.com/conferences.
About the Rosetta Syllego System
The Rosetta Syllego system is Rosetta Biosoftware's practical solution for genetic data management and analysis. Designed for scientists engaged in genetic studies, such as eQTL or genome-wide association or linkage, the system is a resource for managing genetic variation information. The system captures and stores SNP genotyping assay data and information from leading technology platforms so that you can better plan and execute genetic studies. QC tools help you verify that data are high-quality to prevent loss of time in downstream analyses.
Application tools enable you to combine relevant genotypic and phenotypic study data to interface with the statistical environment of your choice.
And automation tools enable you to analyze and catalog study data and analysis results, so that you can incorporate findings into future studies. Because the system is built upon Rosetta Biosoftware's existing informatics platform, it can integrate with other Rosetta Biosoftware products, your own in-house tools, or other third-party platforms. For more information on the Syllego system, please visit www.rosettabio.com/syllego.
About Rosetta Biosoftware
Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its comprehensive software solutions, including the Rosetta Resolver, Rosetta Elucidator, and Rosetta Syllego systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. (NYSE:MRK). More information about Rosetta Biosoftware is available at www.rosettabio.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics' technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics' technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2005, and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference.
Rosetta Resolver and Rosetta Elucidator are U.S. registered trademarks of Rosetta Inpharmatics LLC. Rosetta Syllego is a trademark of Rosetta Inpharmatics LLC.
CONTACT: Rosetta Biosoftware Lisa Owen 206-926-1236
CONTACT: Rosetta Biosoftware Lisa Owen 206-926-1236 , ,
Source: Business Wire (Business Wire India)